| Bioactivity | TMX-3013 is a CDKs inhibitor capable of inhibiting the activity of CDK1, CDK2, CDK4, CDK5, and CDK6, with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be utilized for synthesizing PROTACs that feature a polyethylene glycol (PEG) linker arm and Thalidomide (HY-14658) as the CRBN-recruiting arm[1]. |
| CAS | 2488761-18-6 |
| Formula | C17H14BrFN6O3S |
| Molar Mass | 481.30 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Teng M, et al. Development of CDK2 and CDK5 dual degrader TMX‐2172[J]. Angewandte Chemie, 2020, 132(33): 13969-13974. |
TMX-3013
CAS: 2488761-18-6 F: C17H14BrFN6O3S W: 481.30
TMX-3013 is a CDKs inhibitor capable of inhibiting the activity of CDK1, CDK2, CDK4, CDK5, and CDK6, with IC50 values of
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.